The role of non-opioid alternatives in cataract surgery pain management

Post author:

#OMIDRIA

This retrospective study demonstrated a reduction in the quantity of opioids prescribed for patients receiving OMIDRIA during cataract surgery. The study also hypothesized that the use of OMIDRIA intraoperatively may decrease patient exposure to opioids after cataract surgery as well as the volume of pills potentially diverted into the community.

Trending publications / white papers

Publication / Delivering a Dropless Pathway in Cataract Surgery

Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and...

#OMIDRIA

Publication / Blocking the Inflammatory Cascade

Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract...

#OMIDRIA

Publication / Controlling postoperative inflammation and associated complications with OMIDRIA

Dr. Visco discusses the surgical and patient benefits of continuous intracameral administration of OMIDRIA.

#OMIDRIA

Related publications / white papers

Publication / Delivering a Dropless Pathway in Cataract Surgery

Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and can potentially exceed – the current standard of care in cataract surgery regimens.

#OMIDRIA

Publication / Blocking the Inflammatory Cascade

Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract surgery, encompassing a reduced postoperative drop regimen and an enhanced patient journey.

#OMIDRIA

Publication / Making Cataract Surgery Child’s Play

Dr. Wilson shares his study results demonstrating that OMIDRIA is safe for use in children and maintained mydrias during cataract surgery.

#OMIDRIA

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.